NASDAQ:OKUR OnKure Therapeutics (OKUR) Stock Price, News & Analysis $2.04 +0.03 (+1.49%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$2.03 -0.01 (-0.49%) As of 08/8/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About OnKure Therapeutics Stock (NASDAQ:OKUR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get OnKure Therapeutics alerts:Sign Up Key Stats Today's Range$1.97▼$2.0850-Day Range$2.01▼$2.9952-Week Range$1.70▼$20.00Volume76,397 shsAverage Volume75,286 shsMarket Capitalization$27.56 millionP/E RatioN/ADividend YieldN/APrice Target$32.33Consensus RatingBuy Company Overview OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO. Read More OnKure Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreOKUR MarketRank™: OnKure Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 580th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingOnKure Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOnKure Therapeutics has received no research coverage in the past 90 days.Read more about OnKure Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for OnKure Therapeutics are expected to grow in the coming year, from ($4.05) to ($3.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OnKure Therapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OnKure Therapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOnKure Therapeutics has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about OnKure Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for OKUR. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOnKure Therapeutics does not currently pay a dividend.Dividend GrowthOnKure Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for OKUR. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 6 people have searched for OKUR on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added OnKure Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, OnKure Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,404,150.00 in company stock.Percentage Held by InsidersOnly 2.30% of the stock of OnKure Therapeutics is held by insiders.Percentage Held by Institutions90.98% of the stock of OnKure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OnKure Therapeutics' insider trading history. Receive OKUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OnKure Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address OKUR Stock News HeadlinesOKUR OnKure Therapeutics, Inc.June 12, 2025 | seekingalpha.comMajor Shareholder Sells Thousands of OnKure Therapeutics Shares!May 14, 2025 | tipranks.comBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. August 9 at 2:00 AM | Crypto 101 Media (Ad)Promising Developments and Positive Trial Results Reinforce Buy Rating for OnKure TherapeuticsMay 9, 2025 | tipranks.comOnKure Therapeutics, Inc.: OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | finanznachrichten.deOnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights | OKUR ...May 6, 2025 | gurufocus.comOnKure Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | gurufocus.comOnKure Therapeutics Reports First Quarter 2025 Financial Results and Business HighlightsMay 6, 2025 | globenewswire.comSee More Headlines OKUR Stock Analysis - Frequently Asked Questions How have OKUR shares performed this year? OnKure Therapeutics' stock was trading at $8.60 on January 1st, 2025. Since then, OKUR shares have decreased by 76.3% and is now trading at $2.04. How were OnKure Therapeutics' earnings last quarter? OnKure Therapeutics, Inc. (NASDAQ:OKUR) released its quarterly earnings data on Tuesday, May, 6th. The company reported ($1.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.41) by $0.22. Who are OnKure Therapeutics' major shareholders? OnKure Therapeutics' top institutional investors include Bailard Inc. (0.11%). Insiders that own company stock include Jason A Leverone and Nicholas A Saccomano. View institutional ownership trends. How do I buy shares of OnKure Therapeutics? Shares of OKUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/06/2025Today8/09/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OKUR Previous SymbolNASDAQ:OKUR CIK1637715 Webreneopharma.com Phone858-283-0280FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for OnKure Therapeutics$32.33 High Price Target$34.00 Low Price Target$30.00 Potential Upside/Downside+1,485.0%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($5.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$52.67 million Net MarginsN/A Pretax MarginN/A Return on Equity-49.13% Return on Assets-45.72% Debt Debt-to-Equity RatioN/A Current Ratio11.18 Quick Ratio11.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.78 per share Price / Book0.26Miscellaneous Outstanding Shares13,510,000Free Float13,199,000Market Cap$27.56 million OptionableN/A Beta0.40 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:OKUR) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OnKure Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share OnKure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.